Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R C Donehower

Showing results (121-130 of 129) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 129 results.
Annals of the New York Academy of Sciences|December 13, 1996
Factors affecting topotecan sensitivity in human leukemia samplesS H Kaufmann, S D Gore, L Letendre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependenceE K Rowinsky, S H Kaufmann, S D Baker, et al.
Cancer Chemotherapy and Pharmacology|November 17, 2001
Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumorsE I Heath, S O'Reilly, R Humphrey, et al.
British Journal of Cancer|October 1, 2014
A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumoursB A Wilky, M A Rudek, S Ahmed, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemiaS D Gore, E K Rowinsky, C B Miller, et al.
International Journal of Radiation Oncology, Biology, Physics|November 10, 2000
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survivalA Chakravarthy, R A Abrams, C J Yeo, et al.
Oncogene|November 26, 2008
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assayA Jimeno, A Chan, G Cusatis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemiaS D Gore, L J Weng, S Zhai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2001
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activationE M Jaffee, R H Hruban, B Biedrzycki, et al.
Pageof 13

Showing results (121-130 of 129) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 129 results.
Annals of the New York Academy of Sciences|December 13, 1996
Factors affecting topotecan sensitivity in human leukemia samplesS H Kaufmann, S D Gore, L Letendre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependenceE K Rowinsky, S H Kaufmann, S D Baker, et al.
Cancer Chemotherapy and Pharmacology|November 17, 2001
Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumorsE I Heath, S O'Reilly, R Humphrey, et al.
British Journal of Cancer|October 1, 2014
A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumoursB A Wilky, M A Rudek, S Ahmed, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemiaS D Gore, E K Rowinsky, C B Miller, et al.
International Journal of Radiation Oncology, Biology, Physics|November 10, 2000
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survivalA Chakravarthy, R A Abrams, C J Yeo, et al.
Oncogene|November 26, 2008
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assayA Jimeno, A Chan, G Cusatis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemiaS D Gore, L J Weng, S Zhai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2001
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activationE M Jaffee, R H Hruban, B Biedrzycki, et al.
Pageof 13